 neo-adjuv pre-empt cisplatin therapi invas transit cell carcinoma bladder pilot studi respons rate intraven cisplatin transit cell carcinoma bladder definit treatment west midland urolog research group wmurg australian bladder cancer studi group abcsg randomis trial surviv benefit neo-adjuv intraven cisplatin transit cell carcinoma bladder trial target number patient west australia similar treatment protocol elig criteria overview analysi total number patient treatment group control group differ overal result differ surviv control patient odd ratio control group chemotherapi group patient confid interv odd ratio wide clear evid worthwhil benefit neo-adjuv cisplatin approach studi combin treatment activ metastat diseas